Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer

NCT01050842 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer
Adenocarcinoma of the Prostate
Hormone-resistant Prostate Cancer
Stage IV Prostate Cancer

Interventions

DRUG: bicalutamide
DRUG: raloxifene
PROCEDURE: quality-of-life assessment

Sponsor

Mayo Clinic